Author:
Zeng Jia,Zuo Jing,Li Ning,Yao HongWen,Zhang YuanYuan,Zhao YuXi,Wang TianTian,Xiu Lin,Li Jian,Yu Jing,Liang LeiLei,Wu LingYing
Abstract
Abstract
Objective
To investigate the influencing factors of the recurrence of IB1-IIA2 cervical squamous cell carcinoma after surgical treatment, and to explore the relationship between high-risk human papillomavirus (HR-HPV) infection and postoperative cervical squamous cell carcinoma recurrence.
Methods
Patients (n = 312) diagnosed with stage IB1-IIA2 cervical cancer and treated by radical hysterectomy and lymphadenectomy at this hospital were accrued between January 2014 and December 2016. The clinical data of these patients were analysed, and the association among clinicopathological factors, the association among clinicopathological factors, HPV infection and recurrences was investigated through Cox regression.
Results
The median follow-up time was 59.2 months (with a range of 14–77.9 months). The pre-operative HPV infection rate was 85.3% (266/312), and 74 patients had a high level of HPV-DNA (> 5 × 106 copy number / 104 cells). Twenty-nine patients had a postoperative persistent high level of HPV-DNA (9.3%). On multivariate analysis, deep 1/3 stromal invasion (hazard ratio [HR] 114.79, 95% confidence interval [CI] 2.821–4670.111, p = 0.012*) and postoperative persistence of high HPV-DNA levels within 12 months (HR 269.044, 95% CI 14.437–5013.754, p < 0.001*) and 24 months (HR 31.299, 95% CI 1.191–822.215, p = 0.039*) were associated with a higher local recurrence rate.
Conclusion
Continuous high HPV-DNA levels within 24 months of an operation and deep 1/3 interstitial infiltration were independent risk factors for local recurrences of cervical cancer.
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Reproductive Medicine,General Medicine
Reference34 articles.
1. Wei M, Zhou W, Bi Y, Wang H, Liu Y, Zhang ZJ. Rising mortality rate of cervical cancer in younger women in urban China. J Gen Intern Med. 2019;34(2):281–4. https://doi.org/10.1007/s11606-018-4732-z.
2. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-203. https://doi.org/10.1016/S2214-109X(19)30482-6.
3. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(1):64–84. https://doi.org/10.6004/jnccn.2019.0001.
4. Zhang J, Lu Q, Shi NM, Li L, Liu GG, Zhang Z, et al. Investigation on asymptomatic infection and influencing factors of high-risk human papillomavirus in women. China Vaccine Immun. 2019;25(03):296–8.
5. Bogani G, Sopracordevole F, Di Donato V, Ciavattini A, Ghelardi A, Lopez S, et al. High-risk HPV-positive and -negative high-grade cervical dysplasia: analysis of 5-year outcomes. Gynecol Oncol. 2021;161(1):173–8. https://doi.org/10.1016/j.ygyno.2021.01.020.